Published in Lancet Oncol on October 31, 2011
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl (2014) 3.11
Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl (2013) 2.53
Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology (2014) 1.52
Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer (2012) 1.24
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Cancer review: Cholangiocarcinoma. J Carcinog (2015) 1.17
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol (2014) 1.12
Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl (2015) 1.06
Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol (2014) 1.03
HCC: current surgical treatment concepts. Langenbecks Arch Surg (2012) 1.03
Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma. Liver Cancer (2012) 1.02
Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol (2012) 1.01
Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer (2014) 1.00
Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer (2012) 0.99
Hepatocellular carcinoma: A comprehensive review. World J Hepatol (2015) 0.98
Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97
Management of hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.96
Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol (2015) 0.95
Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology (2015) 0.92
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol (2013) 0.92
Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features. Stem Cells Int (2015) 0.91
New advances in hepatocellular carcinoma. World J Hepatol (2016) 0.91
Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol (2014) 0.90
Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol (2013) 0.89
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol (2015) 0.89
Quality of life, risk assessment, and safety research in liver transplantation: new frontiers in health services and outcomes research. Curr Opin Organ Transplant (2012) 0.87
A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology (2015) 0.87
Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 0.87
Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci (2013) 0.85
Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford) (2014) 0.84
Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria. PLoS One (2014) 0.84
Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol (2015) 0.84
Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford) (2012) 0.83
Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83
Poor level of agreement on the management of postoperative pancreatic fistula: results of an international survey. HPB (Oxford) (2012) 0.83
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology (2016) 0.82
Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol (2014) 0.82
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg (2014) 0.82
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2013) 0.82
Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma. J Clin Exp Hepatol (2014) 0.81
Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol (2014) 0.81
Progress in abdominal organ transplantation. Med Sci Monit (2011) 0.81
Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol (2015) 0.81
Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today (2016) 0.81
Leadership: ten tips for choosing an academic chair. Nature (2015) 0.80
Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol (2015) 0.80
Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience. Liver Transpl (2014) 0.80
Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol (2015) 0.80
Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther (2016) 0.80
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol (2014) 0.80
Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford) (2012) 0.79
Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. Medicine (Baltimore) (2015) 0.79
Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann Gastroenterol (2015) 0.79
Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant (2015) 0.78
Induced maturation of hepatic progenitor cells in vitro. Braz J Med Biol Res (2013) 0.78
Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol (2014) 0.78
Hepatocellular carcinoma. Wien Med Wochenschr (2014) 0.78
Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol (2016) 0.78
Liver transplantation for malignancy: current treatment strategies and future perspectives. World J Gastroenterol (2014) 0.78
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol (2017) 0.78
Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol (2015) 0.78
The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. Ann Surg Oncol (2016) 0.77
Liver transplantation for hepatocellular carcinoma: time for an international consensus. Clin Res Hepatol Gastroenterol (2012) 0.77
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol (2015) 0.77
Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol (2015) 0.77
A systematic review of pharmacological treatment options used to reduce ischemia reperfusion injury in rat liver transplantation. PLoS One (2015) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg (2017) 0.76
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol (2016) 0.76
Wait Time of < 6 and > 18 Months Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation (2017) 0.76
Liver transplantation in 2012: Transplantation for liver cancer--more with better results. Nat Rev Gastroenterol Hepatol (2013) 0.76
Analysis of the relationship between liver regeneration rate and blood levels. Pak J Med Sci (2015) 0.75
Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World J Gastroenterol (2014) 0.75
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis (2014) 0.75
Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular Carcinoma. Int J Mol Sci (2016) 0.75
Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. Int J Mol Sci (2016) 0.75
De novo Hepatocellular Carcinoma after Liver Transplantation. J Clin Transl Hepatol (2015) 0.75
Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. Sci Rep (2015) 0.75
Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg (2012) 0.75
A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointest Tumors (2016) 0.75
Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) (2013) 0.75
Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. Mod Pathol (2016) 0.75
Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol (2016) 0.75
Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr (2016) 0.75
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol (2016) 0.75
Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One (2013) 0.75
The multiple aspects of liver transplantation for hepatocellular carcinoma: comments on the recommendations from the consensus conference. Hepatobiliary Surg Nutr (2014) 0.75
Laparoscopic Resection of Recurrence from Hepatocellular Carcinoma after Liver Transplantation: Case Reports and Review of the Literature. Case Rep Oncol Med (2016) 0.75
Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One (2015) 0.75
Long-term survival with repeated resections of recurrent hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature. Ann Transl Med (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (2008) 5.16
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut (2008) 3.65
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg (1989) 3.30
Strategies for safer liver surgery and partial liver transplantation. N Engl J Med (2007) 3.14
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant (2009) 3.09
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol (2003) 2.87
A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology (2007) 2.66
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl (2011) 2.33
Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14
Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant (2008) 2.06
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg (1995) 2.03
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant (2007) 2.00
Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant (2010) 1.93
Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology (1993) 1.90
Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg (2004) 1.71
Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant (2007) 1.70
Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant (2006) 1.66
Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg (2008) 1.65
Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol (2010) 1.59
Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol (2004) 1.57
Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg (2007) 1.56
Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut (2005) 1.54
Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations. Liver Transpl (2011) 1.52
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology (2004) 1.45
Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl (2006) 1.41
The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol (2007) 1.30
Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl (2005) 1.30
Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg (2001) 1.29
Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant (2009) 1.27
Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl (2005) 1.27
Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl (2007) 1.27
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant (2008) 1.18
The surgical approach to HCC: our progress and results in Japan. Liver Transpl (2004) 1.15
Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol (2009) 1.14
18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant (2009) 1.12
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl (2009) 1.10
Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2005) 1.10
Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol (2009) 1.06
Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg (2004) 1.06
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol (2010) 1.05
Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl (2011) 1.02
Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl (2011) 1.02
Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl (2011) 1.01
Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. Transplant Proc (2009) 1.01
Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer (1994) 0.99
Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transpl (2011) 0.96
Living donor liver transplantation: The ethics and the practice. Hepatology (2008) 0.94
Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2007) 0.94
Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl (2011) 0.93
Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl (2011) 0.92
Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl (2011) 0.90
Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant (2005) 0.90
Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl (2011) 0.88
Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg (2007) 0.88
Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl (2011) 0.87
Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int (2010) 0.87
Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg (1999) 0.87
Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation--a clinical and histological examination. Clin Transplant (2006) 0.86
Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci (2007) 0.86
Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl (2011) 0.86
Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant (2007) 0.86
A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int (2006) 0.85
Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg (2005) 0.83
2010 International Consensus Conference on Liver Transplantation for Hepatocellular Carcinoma: texts of experts. Liver Transpl (2011) 0.83
Is tumor biopsy necessary? Liver Transpl (2011) 0.83
Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2011) 0.82
Immunosuppression and hepatocellular carcinoma. Liver Transpl (2011) 0.82
What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl (2011) 0.80
What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl (2011) 0.80
Place of liver transplantation in the treatment of hepatocellular carcinoma in the normal liver. Liver Transpl (2011) 0.80
Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol (2007) 0.79
[Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi (2005) 0.79
[Clinical study of adjuvant individualized chemotherapy for hepatocellular carcinoma after liver transplantation]. Zhonghua Wai Ke Za Zhi (2004) 0.79
[Value of perioperative adjuvant therapy in liver transplantation for advanced hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao (2007) 0.79
Should we perform deceased donor liver transplantation after living donor liver transplantation has failed? Liver Transpl (2011) 0.78
Inhibition of mammalian target of rapamycin: two goals with one shot? J Hepatol (2010) 0.78
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol (2003) 16.17
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med (2011) 15.02
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med (2010) 10.21
Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet (2003) 7.91
The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54
Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med (2004) 6.87
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet (2011) 6.25
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Systematic reviews of diagnostic test accuracy. Ann Intern Med (2008) 4.84
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Quality councils as health system performance and accountability mechanisms: the Cancer Quality Council of Ontario experience. Healthc Pap (2006) 4.14
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med (2006) 3.70
Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med (2002) 3.61
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology (2004) 3.55
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med (2006) 3.51
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Evidence of bias and variation in diagnostic accuracy studies. CMAJ (2006) 3.34
Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet (2008) 3.33
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg (2004) 2.97
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med (2005) 2.51
Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. J Clin Epidemiol (2008) 2.50
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Life and death by death receptors. FASEB J (2009) 2.39
Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg (2006) 2.37
Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulmonary embolism. Am J Med (2002) 2.37
Imaging strategies for detection of urgent conditions in patients with acute abdominal pain: diagnostic accuracy study. BMJ (2009) 2.35
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
A computerized handheld decision-support system to improve pulmonary embolism diagnosis: a randomized trial. Ann Intern Med (2009) 2.27
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery (2006) 2.24
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Donor information for living donor liver transplantation: where can comprehensive information be found? Liver Transpl (2012) 2.21
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med (2006) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg (2003) 2.03
Nutritional assessment: lean body mass depletion at hospital admission is associated with an increased length of stay. Am J Clin Nutr (2004) 2.03
Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol (2006) 2.02
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem (2005) 1.98
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ (2012) 1.93
Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease. Arch Surg (2003) 1.92
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int (2003) 1.87
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. Radiology (2005) 1.84
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg (2005) 1.76
Pulmonary embolism. BMJ (2010) 1.74
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med (2008) 1.71
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril (2003) 1.71
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg (2010) 1.70
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66
Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63